Article: Spectrum Pharmaceuticals Announces Agreement With GlaxoSmithKline to Settle Imitrex(R) Injection Patent Litigation.

Spectrum Filed ANDA With Paragraph IV Certification for Sumatriptan Injection in October 2004 and Received Tentative Approval From the FDA in October 2006

IRVINE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Spectrum Pharmaceuticals, Inc. today announced that it has settled a patent litigation with GlaxoSmithKline relating to sumatriptan injection, the generic version of GlaxoSmithKline's Imitrex Injection.

The confidential terms of the settlement, which remain subject to government review, provide that Spectrum may exclusively distribute authorized generic versions of certain sumatriptan injection products in the United States with an expected launch ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!